Ding Wang

485 citations
21 papers · 355 indexed · h-index 12
Topics
Protein Degradation and Inhibitors (3 papers)RNA modifications and cancer (3 papers)Cancer-related molecular mechanisms research (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Ding Wang

18 papers receiving 353 citations

Peers

Ding Wang
Comparison fields: 5 of 63
  • Molecular Biology 236
  • Cancer Research 130
  • Pulmonary and Respiratory Medicine 61
  • Oncology 59
  • Biomedical Engineering 42
Replace Soojin Park with:
Soojin Park South Korea
Levi Arnold United States
Michela Romano Italy
Sunsook Hwang South Korea
Eunkyong Ko South Korea
Marcela Cristina Robaina Brazil
Moon Nian Lim Malaysia
Magali Espinosa Mexico
Ziming Huang China
Nima Niknejad Canada
Ding Wang relative to Soojin Park South Korea Soojin Park's profile →
Citations per field
00.5×
Soojin Park · 1×
Citations per year

Countries citing papers authored by Ding Wang

Since Specialization
Citations

This map shows the geographic impact of Ding Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ding Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ding Wang more than expected).

Fields of papers citing papers by Ding Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ding Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ding Wang. The network helps show where Ding Wang may publish in the future.

Co-authorship network of co-authors of Ding Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Ding Wang. A scholar is included among the top collaborators of Ding Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ding Wang. Ding Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 0
3 6
4 0
5 14
6 10
7 45
8 20
9 25
10 14
11 18
12 13
13 54
14 4
15 27
16 4
17 11
18 8
19 12
20
Implementation of management system with longitudinal synthesized structure based on B/S and C/S modes
0

About Ding Wang

Ding Wang is a scholar working on Cancer Research, Biotechnology and Molecular Medicine, having authored 21 papers that have together received 355 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (3 papers), RNA modifications and cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). The work is most often cited by research in Cancer Research (130 citations), Molecular Biology (236 citations) and Biotechnology (24 citations). Ding Wang has collaborated with scholars based in China and United States. Frequent co-authors include Baofeng Guo, Libo Xu, Dhan V. Kalvakolanu, Xiaodong Wei, Hang Liang, Qian Wang, Hongwu Zheng, Yang Li, Zhong Chen and Xiaohui Jiang. Their work appears in journals such as Frontiers in Immunology, Gene and Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026